1-Phenyl-4-pyrrolidin-1-yl-2,3-dihydro-1H-pyrrolo[2,3-b]quinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-Phenyl-4-pyrrolidin-1-yl-2,3-dihydro-1H-pyrrolo[2,3-b]quinoline
• 英文别名: 1-Phenyl-4-pyrrolidin-1-yl-2,3-dihydropyrrolo[2,3-b]quinoline
• 化学式: C₂₁H₂₁N₃
• 分子量: 315.418
• InChiKey: MGMJHJOCWJIHAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  19.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-苯基-2-吡咯烷酮 在 正丁基锂 、 三氯氧磷 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 8.0h， 生成 1-Phenyl-4-pyrrolidin-1-yl-2,3-dihydro-1H-pyrrolo[2,3-b]quinoline
  参考文献：
  名称：

  A novel and highly efficient synthesis of the aza analogs of tacrine

  摘要：

  We describe a new and efficient synthesis of the aza analogs of tacrine based upon the chemistry of the anionically activated trifluoromethyl group. We identify four sites (A-D) which can be successfully altered to afford the desired fused tricyclic heterocycles in high yield (63-82%). The reaction is believed to proceed through the formation of a quinone methide intermediate. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)01122-3

文献信息

• PROTECTED ANTIBODY-DRUG AND APTAMER-DRUG CONJUGATES
  申请人：Kosak Kenneth Michael

  公开号：US20210198671A1

  公开（公告）日：2021-07-01

  This is a Continuation in Part (CIP), and Nonprovisional U.S. Patent Application of Provisional U.S. Patent Application No. 62/786,340, filed Dec. 29, 2018, (herein called App. 62/786,340), the entire contents, including suitable methods and examples, and references therein which are hereby incorporated by reference as if fully set forth herein. All patent applications, patents, and publications, including supplementary materials, and additional references therein, that are cited herein, are hereby incorporated herein by reference in their entireties, except for any conflicting definitions, subject matter disclaimers or disavowals, and except to the extent that the incorporated material is inconsistent or in conflict with the express disclosures herein, in which case the language in this disclosure controls. For this invention, certain useful compositions and synthesis methods, and all categories of active agents, ligands, all intercalators of nucleic acids and peptides, any antibodies, any nucleic acids, including carrier nucleic acid compositions, peptide nucleic acids (PNA) and derivatized nucleic acids, splicing RNA (spRNA), DNAzymes, any polymers, targeting moieties, target substances including cancer cells, disease microorganisms and biomarkers, coupling agents and functional groups, are all suitably modified as needed. All compositions that would be useful for this invention after suitable modification, defined herein, including crRNAs, sgRNAs, any CRISPR proteins and compositions, any zinc finger proteins and compositions, any TALEN proteins and compositions and any suitable derivatives thereof.